Alberta Signs $162M Deal to Expand Access to Rare Disease Drugs

The agreement with Canada’s federal government will fund new treatments, diagnostics, and screening for rare diseases over three years.

The Governments of Alberta and Canada have signed a $162 million bilateral agreement under the National Strategy for Drugs for Rare Diseases.
The funding will improve access to three specific drugs: Poteligeo for Sézary syndrome, Oxlumo for hyperoxaluria type 1, and Epkinly for large B-cell lymphoma.
The agreement also includes plans to enhance early diagnosis and screening for rare diseases across Alberta.
This initiative is part of a larger $1.5 billion federal investment to support rare disease treatment nationwide, with Alberta being the third province to join the strategy.
The deal emphasizes collaboration between provinces and territories to develop a common list of drugs and improve real-world data collection for future health policy decisions.